SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological therapeutic options. The beneficial effects of relaxin peptide treatment have been demonstrated previously in clinically relevant animal models of liver disease. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaftanovskaya, Elena, Ng, Hooi Hooi, Rivas, Bryan, Myhr, Courtney, Shupe, Thomas, Hu, Xin, Ferrer, Marc, Southall, Noel, Wilson, Kenneth, Marugan, Juan, Bishop, Colin, Agoulnik, Irina, Agoulnik, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Non-Steroid Hormone Signaling
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552156/
http://dx.doi.org/10.1210/js.2019-SAT-035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552156/
http://dx.doi.org/10.1210/js.2019-SAT-035

Ejemplares similares